Brief: Cytodyn Files A Phase 2 Protocol With The FDA For Leronlimab (PRO 140) And Regorafenib As A Combination Therapy For Metastatic Colorectal Cancer
08/08/2019 11:28
Aug 8 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN FILES A PHASE 2 PROTOCOL WITH THE FDA FOR
LERONLIMAB
(PRO 140) AND REGORAFENIB AS A COMBINATION THERAPY FOR
METASTATIC COLORECTAL CANCER
Source text for Eikon: ID:nGNX1bRJhd
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer